Answers are grounded in this paper and cite their sources.
Acute agitation in pediatric patients presents significant challenges in acute psychiatric settings. Substance use may complicate management, yet data examining treatment outcomes in this population remain limited. This study examined whether substance use was associated with differences in presentation characteristics, treatment patterns, and outcomes among youth receiving intramuscular (IM) antipsychotics for agitation. A retrospective review was conducted of pediatric patients who received IM chlorpromazine or haloperidol for acute agitation across a large health system from 2019–2023. Patients were categorized based on documented substance use (positive urine drug screening or clinical documentation). Groups were compared on demographics, clinical characteristics, medication use, repeat IM medication administration, restraint or seclusion, and adverse events. Survival analysis examined time to repeat medication administration, and logistic regression evaluated predictors of adverse vital-sign events. Among 150 patients (mean age 12 years), 47 (31.3%) had documented substance use. Patients with substance use were older (14.1 vs. 11.3 years, p < 0.001), more likely to present with police involvement (40.4% vs. 8.7%, p < 0.001) and be treated in the emergency department (68.1% vs. 48.5%, p = 0.026). Medication selection, benzodiazepine coadministration, restraint or seclusion, repeat IM medication, time to re-administration, and rates of adverse events did not differ between groups. Substance use was associated with differences in the circumstances of presentation, but was not associated with differences in short-term pharmacologic efficacy or safety outcomes among pediatric patients treated with IM antipsychotics for agitation.
No takes yet. Share an insight, caveat, or question.
Chaia et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: